18 news items
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
ABBV
CI
CVS
7 Jun 24
biosimilar interchangeability. The government and lawmakers are also scrutinizing PBM agreements with drugmakers.
According to J&J CFO
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian Cancer
ABBV
6 Jun 24
, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
ABBV
6 Jun 24
in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
ABBV
6 Jun 24
, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383
ABBV
5 Jun 24
in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional
zw2zv7f otv63weivcd15vsy4sy8h6ies6
ABBV
4 Jun 24
, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws
hmjm3naft1pr hw3v4q2rizzuqfbon0e
ABBV
31 May 24
inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry
ywjghzvtys07h7fy8xh1ofrtgv7
ABBV
ACAD
BAYRY
24 May 24
filing a notice with government regulators, Cencora publicly acknowledged the breach on February 27.
Despite the disclosure, the company
iqexk9ci1v27qynsj gw9im2
ABBV
LABP
23 May 24
, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic
hayc54xy9d6uddz0eazp9cjw8hmdbmr22qodu
ABBV
17 May 24
, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic
cs6rf5imum6lltmg9qznz2rrt15mgqmkweieauooogjxc83ofq90qc2jyntd
ABBV
13 May 24
, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws
0hqoceny1cjszo10lyjox5aweq5lwv3qcdlt6ndabityqt8ueunvyqbc
ABBV
25 Apr 24
and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about
i8uov3b7l3 up5zfftlzpykztgtr487w3
ABBV
18 Apr 24
, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes
al29iq24b2odnt5x4q9yqel6ilpvv4
ABBV
12 Apr 24
process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about
a5gfdu8i8rn2p8y5pzqjuag88nfr3u8ucngt4owllakiuayr3d 3crk34p
ABBV
AEHR
AKAN
25 Mar 24
Corporation (NASDAQ:CGC) fell 13.1% to $6.68. The German government recently approved
f0gk88msrdlm9vvr3l59jt btxu5qgc
ABBV
25 Mar 24
inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our
s1y20z fmnymwbfki7l79bfcdegvhfrm8ah880tza2gk6hryi4899u
ABBV
LABP
25 Mar 24
or government action, and (xiii) changes to laws and regulations applicable to the industries of the parties. Additional information about the economic
jarszcaqqh4k c2h
ABBV
22 Mar 24
and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional
- Prev
- 1
- Next